BioAtla (NASDAQ:BCAB) Research Coverage Started at Rodman & Renshaw

Rodman & Renshaw initiated coverage on shares of BioAtla (NASDAQ:BCAB) in a research note published on Tuesday morning, MarketBeat Ratings reports. The firm issued a buy rating and a $4.00 price target on the stock.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioAtla in a research note on Friday, January 9th. One research analyst has rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $4.00.

BioAtla Stock Performance

Shares of BioAtla stock opened at $0.32 on Tuesday. The firm has a market cap of $18.79 million, a P/E ratio of -0.28 and a beta of 1.04. The firm’s 50-day simple moving average is $0.72 and its 200-day simple moving average is $0.60. BioAtla has a twelve month low of $0.24 and a twelve month high of $1.43.

BioAtla (NASDAQ:BCAB) last announced its quarterly earnings results on Thursday, November 13th. The company reported ($0.27) EPS for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.04. On average, equities analysts forecast that BioAtla will post -1.46 earnings per share for the current fiscal year.

Institutional Investors Weigh In On BioAtla

A number of large investors have recently bought and sold shares of BCAB. Woodline Partners LP bought a new position in BioAtla in the 1st quarter valued at $26,000. Sheets Smith Investment Management acquired a new stake in shares of BioAtla in the third quarter valued at $46,000. Susquehanna International Group LLP increased its stake in shares of BioAtla by 237.6% in the third quarter. Susquehanna International Group LLP now owns 252,583 shares of the company’s stock valued at $174,000 after buying an additional 177,760 shares in the last quarter. Millennium Management LLC bought a new position in shares of BioAtla in the third quarter valued at about $235,000. Finally, Acadian Asset Management LLC lifted its position in BioAtla by 968.9% during the 1st quarter. Acadian Asset Management LLC now owns 1,690,110 shares of the company’s stock worth $585,000 after buying an additional 1,531,994 shares in the last quarter. 77.23% of the stock is currently owned by institutional investors.

BioAtla Company Profile

BioAtla, Inc (NASDAQ: BCAB) is a clinical‐stage biotechnology company focused on the development of conditionally active biologics (CABs) for oncology and other serious diseases. Utilizing its proprietary CAB technology platform, BioAtla engineers monoclonal antibodies, bispecifics and antibody-drug conjugates that remain inactive in healthy tissues but become activated in the tumor microenvironment. This targeted approach aims to improve therapeutic index by enhancing anti‐tumor potency while minimizing off-target effects and systemic toxicity.

Founded in 2012 and headquartered in San Diego, California, BioAtla has advanced multiple product candidates into clinical trials.